Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Second or Late-Line Esophageal Squamous Cell Carcinoma
NCT01993784Phase 2Unknown
- Sponsor
- Peking University
- Start
- Aug 2013
- Primary completion
- Mar 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01993784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01993784.